Pazopanib in Treating Patients With Malignant Pleural Mesothelioma

Status Completed

Clinical Trial Summary

This phase II trial is studying the side effects and how well pazopanib works in treating patients with malignant pleural mesothelioma. Pazopanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.

Clinical Trial Description

PRIMARY OBJECTIVES:

I. Determine the effect of pazopanib hydrochloride on the proportion of patients with malignant pleural mesothelioma who are progression-free at 6 months based on the RECIST criteria.

II. Determine the clinical toxicities of this drug in this patient population.

SECONDARY OBJECTIVES:

I. Determine the objective tumor response status in these patients as measured by the RECIST criteria or the modified RECIST criteria.

II. Determine the response rate in patients treated with this drug. III. Determine the effect of this drug on overall survival and time to progression in these patients.

IV. Assess predictive markers of activity of this drug in these patients. V. Assess serologic markers of target inhibition by this drug in these patients.

VI. Determine the clinical toxicities of this drug in this patient population.

OUTLINE: This is a multicenter study.

Patients receive oral pazopanib hydrochloride once daily on days 1-21. Treatment repeats every 21 days for 2 years in the absence of disease progression or unacceptable toxicity.

Blood is collected at baseline and prior to each course of therapy and analyzed for markers of angiogenesis.

After completion of study therapy, patients are followed every 3 months. ;

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00459862
Study type	Interventional
Source	National Cancer Institute (NCI)
Contact
Status	Completed
Phase	Phase 2
Start date	March 2007
Completion date	May 2013

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00025207` - Gefitinib in Treating Patients With Malignant Mesothelioma	Phase 2
Completed	`NCT00107432` - Sorafenib Tosylate in Treating Patients With Malignant Mesothelioma.	Phase 2
Terminated	`NCT00028782` - EF5 in Detecting Oxygen Level and Blood Vessels in Tumor Cells of Patients Undergoing Photodynamic Therapy for Intraperitoneal or Pleural Cancer	N/A
Completed	`NCT00027703` - Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Malignant Mesothelioma	Phase 2
Recruiting	`NCT04213794` - Heated Intra-peritoneal Chemotherapy With Doxorubicin and Cisplatin for Abdominal for Pelvic Tumors in Pediatric Patients	Early Phase 1
Completed	`NCT01503177` - Intrapleural Measles Virus Therapy in Patients With Malignant Pleural Mesothelioma	Phase 1
Completed	`NCT00243074` - S0509 - AZD2171 in Treating Patients With Malignant Pleural Mesothelioma That Cannot Be Removed By Surgery	Phase 2
Completed	`NCT01126346` - Quality of Life and Survivorship Care in Patients Undergoing Hyperthermic Intraperitoneal Chemotherapy (HIPEC)	N/A
Completed	`NCT00039182` - Erlotinib in Treating Patients With Malignant Mesothelioma of the Lung	Phase 2
Withdrawn	`NCT01325753` - Cryotherapy in Treating Patients With Lung Cancer That Has Spread to the Other Lung or Parts of the Body	N/A
Active, not recruiting	`NCT01064648` - Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma	Phase 1/Phase 2
Completed	`NCT00365053` - PXD101 as Second-Line Therapy in Treating Patients With Malignant Mesothelioma of the Chest That Cannot Be Removed By Surgery	Phase 2
Terminated	`NCT01861301` - Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma	Phase 2
Completed	`NCT00392444` - Sunitinib in Treating Patients With Advanced Malignant Pleural Mesothelioma	Phase 2
Completed	`NCT00309946` - Cediranib Maleate in Treating Patients With Malignant Mesothelioma That Cannot Be Removed By Surgery	Phase 2
Completed	`NCT00030498` - Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction	Phase 1
Recruiting	`NCT03420963` - Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors	Phase 1
Withdrawn	`NCT01105390` - AMG 102, Pemetrexed Disodium, and Cisplatin in Treating Patients With Malignant Pleural Mesothelioma	Phase 2